Top 10 Biotech M&A deals all above EUR 10bn

The Top 10 biotech M&A deals ranking (by ticket size) shows that there have been exceptionally large deals in the biotech sector over the last years. The largest deal was the acquisition of Celgene by Bristol Myers Squibb in November 2019 at EUR 72.43bn.

The breakdown by target location shows that half of the targets were located in the US, while the other half were headquartered in Europe. In addition, it is observed that 2020 has been the year with the most Top 10 deals (4 deals).

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: